Executive Summary
Environmental, social, and governance (ESG) priorities are becoming increasingly integrated into how life sciences companies manage operations, supply chains, innovation, workforce strategy, and long-term risk. For pharmaceutical and biotechnology organizations, ESG is not limited to sustainability reporting. It increasingly intersects with manufacturing resilience, clinical research, access to medicines, employee practices, supplier management, and corporate governance.
The industry faces distinctive ESG challenges. Pharmaceutical manufacturing can require significant energy and water resources, clinical research depends on diverse participants and responsible data practices, and global supply chains can create environmental and human-rights exposures. At the same time, companies face increasing expectations for credible sustainability information and stronger oversight of ESG-related risks.
The International Sustainability Standards Board’s IFRS S1 and IFRS S2 provide a global baseline for sustainability- and climate-related financial disclosures, including governance, strategy, risk management, and metrics and targets. (IFRS)
For life sciences leaders, the priority is therefore shifting from standalone ESG initiatives toward measurable programs connected to business strategy, operational resilience, and stakeholder outcomes.
Key Themes
- Climate and resource efficiency are becoming operational priorities.
- Sustainable supply chains require greater visibility and accountability.
- Access and affordability remain central social considerations.
- Workforce, diversity, and responsible clinical research shape the social dimension.
- ESG governance increasingly depends on reliable data, controls, and transparent reporting.
1. Climate Action and Decarbonization
Reducing greenhouse gas emissions is a major environmental priority for life sciences companies. Pharmaceutical organizations operate energy-intensive laboratories, manufacturing facilities, warehouses, and data environments, while global supply chains can contribute significantly to Scope 3 emissions.
Companies are therefore focusing on renewable energy, energy efficiency, electrification, low-carbon manufacturing, and supplier engagement.
Climate strategy is also becoming a risk-management issue. IFRS S2 addresses both physical and transition climate risks and requires relevant disclosures about governance, strategy, risk management, and performance. (IFRS)
2. Sustainable Pharmaceutical Manufacturing
Pharmaceutical manufacturing creates ESG challenges involving energy consumption, water use, solvents, chemicals, waste, and process efficiency.
Sustainable manufacturing strategies can include:
- Energy-efficient production systems
- Lower-carbon process technologies
- Waste reduction and recovery
- Renewable electricity
- More efficient facility design
- Continuous manufacturing where appropriate
The objective is increasingly to improve environmental performance without compromising product quality, patient safety, or regulatory compliance.
3. Water Stewardship
Water is an important resource across pharmaceutical research and manufacturing. It is used in production processes, cleaning, cooling, laboratories, utilities, and facility operations.
Water stewardship is becoming particularly relevant for facilities located in regions facing water stress. Companies can improve resilience through water-use monitoring, process optimization, recycling, wastewater treatment, and site-specific water-risk assessments.
For global organizations, water strategy increasingly needs to consider both operational consumption and local environmental conditions rather than relying solely on company-wide targets.
4. Sustainable and Resilient Supply Chains
Pharmaceutical supply chains span active pharmaceutical ingredients, raw materials, packaging, manufacturing partners, logistics providers, and distribution networks.
ESG programs increasingly require companies to understand environmental and social risks beyond their own facilities. Supplier assessments can address emissions, labor practices, human rights, resource consumption, ethics, and business continuity.
Greater supply-chain transparency can also strengthen resilience by helping companies identify geographic, environmental, and supplier-specific vulnerabilities earlier.
5. Access to Medicines and Health Equity
The social dimension of ESG is particularly significant for life sciences companies because their products directly affect health outcomes.
Access strategies can address affordability, availability, distribution, underserved populations, and differences in healthcare infrastructure. Companies may also consider how clinical development and commercialization strategies affect populations that historically have had limited access to innovative therapies.
Health equity therefore connects ESG with broader questions around product strategy, patient access, public health, and responsible innovation.
6. Diversity and Inclusion
Workforce diversity and inclusion remain important social priorities across pharmaceutical and biotechnology organizations.
Companies are focusing on representation, equitable career development, leadership diversity, inclusive workplace practices, and employee engagement. Diversity is also relevant beyond the workforce, including clinical-trial participation and research populations.
A credible approach requires measurable objectives and transparent progress rather than treating diversity solely as a corporate communications initiative.
7. Responsible Clinical Research
Clinical research creates distinctive ESG responsibilities because pharmaceutical companies work directly with patients and research participants.
Responsible clinical research includes protecting participant rights, maintaining informed consent, ensuring appropriate privacy and data protection, and improving representation across clinical studies.
Greater diversity in clinical trials can help ensure that evidence better reflects the populations ultimately expected to use a therapy. Responsible research practices therefore connect social responsibility with scientific quality and patient trust.
8. Ethical AI and Responsible Data Use
As life sciences companies expand their use of AI across drug discovery, clinical development, medical affairs, manufacturing, and commercial operations, responsible AI is becoming an increasingly important governance priority.
Key considerations include:
- Data privacy and security
- Bias and representativeness
- Model transparency
- Human oversight
- Intellectual property protection
- Appropriate validation
- Accountability for AI-supported decisions
The objective is to ensure that AI delivers business and scientific value without creating unmanaged ethical, regulatory, or societal risks.
9. ESG Data, Reporting, and Transparency
ESG strategy increasingly depends on the quality of the underlying data. Companies need reliable information on emissions, energy, water, waste, workforce metrics, supply-chain risks, and other material sustainability issues.
This is becoming more important as sustainability reporting moves toward standardized, investor-focused disclosure. IFRS S1 requires companies applying the standard to disclose material sustainability-related risks and opportunities through governance, strategy, risk management, and metrics and targets. (IFRS)
Strong ESG data governance can therefore reduce reporting risk while making sustainability performance more measurable and comparable.
10. ESG Governance and Accountability
ESG programs require clear ownership at board and executive levels. Governance structures increasingly need to define who identifies material ESG risks, establishes targets, monitors progress, validates reported information, and integrates sustainability considerations into business decisions.
This is particularly important as ESG becomes connected with enterprise risk management and financial performance.
Effective governance can include board oversight, executive accountability, cross-functional ESG teams, internal controls, assurance processes, and clearly defined performance indicators.
What Makes ESG Different for Life Sciences Companies?
Life sciences organizations face ESG priorities that extend beyond conventional corporate sustainability programs. Their environmental footprint is closely connected to manufacturing and research, while their social impact is directly connected to medicines, clinical research, patients, and healthcare systems.
This creates several interconnected priorities:
- Reducing environmental impact without compromising product quality
- Improving access while supporting sustainable business models
- Strengthening supply-chain resilience and responsible sourcing
- Protecting research participants and sensitive health data
- Ensuring responsible use of AI and emerging technologies
- Building credible and measurable ESG reporting
The strongest strategies integrate these issues into existing quality, risk, compliance, procurement, R&D, and operational systems.
What Will Shape the Future of ESG in Life Sciences?
ESG is likely to become increasingly connected with enterprise risk and strategic planning. Climate exposure, resource availability, supply-chain disruption, workforce risks, access considerations, and technology governance can all influence long-term business resilience.
Nature-related risks are also receiving greater attention. In 2026, the ISSB continued developing its work on nature-related risks and opportunities, building on the broader sustainability disclosure framework established by IFRS S1. (IFRS)
For life sciences companies, this points toward a broader sustainability model in which climate, nature, resources, people, data, and governance are assessed as interconnected business considerations.
Key Takeaways
- Climate action is becoming an important component of pharmaceutical risk management.
- Sustainable manufacturing can reduce resource consumption while supporting operational efficiency.
- Water stewardship is increasingly important for manufacturing resilience.
- Supply-chain ESG visibility is expanding beyond direct operations.
- Access to medicines remains a central social consideration.
- Diversity and inclusion affect both workforce strategy and clinical research.
- Responsible clinical research strengthens patient trust and scientific quality.
- Ethical AI and responsible data use are emerging governance priorities.
- Reliable ESG data is essential for credible reporting.
- Strong governance connects ESG targets with enterprise decision-making.
Conclusion
ESG in life sciences is evolving from a reporting exercise into a broader strategic discipline. Climate action, sustainable manufacturing, water stewardship, responsible supply chains, health equity, workforce practices, clinical research, AI governance, and ESG reporting increasingly intersect with how pharmaceutical and biotechnology companies manage long-term performance and risk.
The next phase will require greater integration. Environmental objectives need to connect with manufacturing and supply-chain strategy, social priorities need to connect with patient and workforce outcomes, and governance needs to ensure that ESG commitments are supported by reliable data and accountable decision-making.
For life sciences leaders, the objective is not simply to establish more ESG initiatives. It is to embed material environmental, social, and governance considerations into the operating model. As sustainability expectations and disclosure frameworks continue to evolve, companies with measurable targets, credible data, and clear executive accountability will be better positioned to manage ESG-related risks while strengthening long-term organizational resilience.
ESG is becoming increasingly important for life sciences companies as organizations face growing expectations around environmental impact, social responsibility, governance, transparency, and sustainable business practices.
1. Climate and Carbon Reduction
Reducing greenhouse-gas emissions is a major ESG priority. Life sciences organizations can evaluate energy consumption, manufacturing emissions, transportation, and facility operations while developing measurable reduction strategies.
2. Sustainable Manufacturing
Pharmaceutical and biotechnology manufacturing can require significant energy, water, and raw materials. ESG programs can encourage more efficient production processes, renewable energy use, waste reduction, and resource conservation.
